News and Announcements
Actinogen Medical’s Progress with Alzheimer’s Trial
- Published September 08, 2016 11:12AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st September 2016, Actinogen
It’s been some months since our last update on Actinogen Medical and the development program for Xanamem™. Over this time we’ve made significant progress in harmonisation of the Phase II XanADu protocol and we have every expectation that all approvals for the study will be in place with the first patients recruited by the end of the year. It’s clear that through the recent interaction with the US Food & Drug Administration (FDA) we have a better, more comprehensive protocol that will provide a stronger data-set for Xanamem™ in the treatment of mild Alzheimer’s disease.
To view the full article, please click on the button below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
